(Disclaimer: This article is only for scientific purposes, in order to protect the patient’s privacy, the relevant information in the following content has been processed) Abstract: A 55-year-old male patient was diagnosed with cellular lymphoma due to enlarged lymph nodes in our hospital, and was treated with a CHOP 6-cycle chemotherapy regimen, as well as symptomatic treatments such as antiemetic, acid-suppressing, and gastric mucous membrane protection, and now the first cycle of chemotherapy has been completed, and the second cycle needs to be carried out. He came to our hospital because he needed to start the second cycle of treatment. After the treatment, he found that the lymph nodes were smaller than before and the disease was under good control. Basic information] Male, 55 years old [Type of disease] Cellular lymphoma (diffuse large B-cell lymphoma) [Hospital] The First Affiliated Hospital of Xi’an Jiaotong University [Time of consultation] December 2020 [Treatment plan] Intravenous injection (gemcitabine hydrochloride, oxaliplatin for injection) + oral drugs (lenalidomide capsule, dexamethasone acetate tablets, rabeprazole sodium enteric capsules, ranitidine hydrochloride capsule) [Treatment plan] Intravenous injection (gemcitabine hydrochloride and oxaliplatin for injection) (Ranitidine Hydrochloride Capsules) 【Treatment Cycle】 Hospitalization for 16 days, regular review 【Treatment Effect】 Effective inhibition of the spread of lesion cells, stable control of the disease I. Initial Consultation Patient: Male, 55 years old. He was found to have multiple enlarged nodules 7 months ago, and was admitted to the Department of Surgery of our hospital 2 months ago for further diagnosis and treatment. After completing the relevant auxiliary examinations, he underwent biopsy of right inguinal lymph node under local anesthesia, and the postoperative pathology results showed that: diffuse large B-cell lymphoma, giant cell mesenchymal variant, and he was initially diagnosed as cellular lymphoma (diffuse large B-cell lymphoma), and was advised to undergo 6 cycles of CHOP, and is currently undergoing the second cycle of chemotherapy to come to the hospital for treatment. The patient came to the hospital for the second cycle of chemotherapy. The patient showed generalized emaciation, with multiple lymph node enlargement in the left axilla and bilateral supraclavicular and mediastinal regions, which had progressed compared with that before the first chemotherapy, and the patient signed the consent to prepare for the second chemotherapy treatment. After the patient was admitted to the hospital, the relevant auxiliary examinations were completed, and the blood routine, liver and kidney functions were normal, and the second chemotherapy was carried out after the contraindication to chemotherapy was ruled out. This time, the treatment followed the first chemotherapy plan, i.e. intravenous injection of gemcitabine hydrochloride and oxaliplatin to prevent cancer cells from spreading or metastasizing, and oral administration of lenalidomide capsule combined with dexamethasone acetate tablets to inhibit cancer cells. Since the patient reported nausea and vomiting after the first chemotherapy, it was considered to be the gastrointestinal adverse reaction caused by chemotherapeutic drugs, which was a normal phenomenon after chemotherapy, therefore, this chemotherapy was given Rabeprazole Sodium Enteric Capsules to protect the gastric mucosa, and Ranitidine Hydrochloride Capsules to inhibit the secretion of gastric acid, so as to avoid the persistence or aggravation of gastrointestinal symptoms. Third, treatment effect After 16 days of hospitalized chemotherapy, the patient’s multiple enlarged lymph nodes in the pelvic cavity were smaller than before, because of her previous good health, she could tolerate chemotherapy treatment. Because the chemotherapy was given orally to protect the gastric mucosa, there were no obvious adverse reactions in the digestive tract, such as nausea and vomiting. According to the telephone follow-up, the patient had no abnormalities in sleep, diet, or bowel movements after the second chemotherapy session, and there was no dizziness, nausea, or abnormal bleeding. The patient was advised to review the routine blood test in one week, pay attention to the time of subsequent chemotherapy, and follow up if he was not feeling well. Precautions Because the patient is positive and optimistic, the body can tolerate chemotherapy drugs, two chemotherapy treatment effect is good, I sincerely feel happy for the patient, I suggest that the daily attention to the following matters: 1, the daily diet should be strengthened nutrition, such as the intake of high-protein foods, such as milk, eggs, etc., should also increase the intake of vegetables and fruits, in a timely manner for the body to replenish the nutrients; 2, usually pay attention to appropriate rest, limit heavy physical labor, avoid overwork. Pay attention to the time of the next cycle of chemotherapy, so as not to interrupt the treatment is not conducive to the treatment; 4, the day before the chemotherapy should return to the hospital for the blood routine and liver and kidney function tests. Although the patient in this case suffered from tumor disease, he had a better mentality, showed positive and optimistic attitude, and completed chemotherapy treatment on time and according to the regulations, so the disease control was more satisfactory, and the patient was seen to recover better, and the volume of some lymphomas was gradually reduced. If such process is followed, the survival time as well as the quality of survival of the patient can be enhanced. Therefore, if there are persistent discomfort symptoms in the body, actively consult a doctor for relevant examinations, and early treatment after a clear diagnosis of the disease can promote the regression of the disease. If the disease is serious, early treatment can effectively improve the survival rate.